140 related articles for article (PubMed ID: 3464812)
21. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
22. Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells.
Aries A; Trentesaux C; Ottolenghi S; Jardillier JC; Jeannesson P; Doubeikovski A
Blood; 1996 Apr; 87(7):2885-90. PubMed ID: 8639908
[TBL] [Abstract][Full Text] [Related]
23. Possible differentiation of human acute myeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-A.
Sakurai M; Sampi K; Hozumi M
Leuk Res; 1983; 7(2):139-43. PubMed ID: 6574295
[TBL] [Abstract][Full Text] [Related]
24. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells.
Long BH; Willis CE; Prestayko AW; Crooke ST
Mol Pharmacol; 1982 Jul; 22(1):152-7. PubMed ID: 6956804
[TBL] [Abstract][Full Text] [Related]
25. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
Seeber S; Loth H; Crooke ST
J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
[TBL] [Abstract][Full Text] [Related]
26. Effects of several anthracycline antitumor antibiotics on the transcriptional activity of isolated nucleoli.
DuVernay VH; Crooke ST
J Antibiot (Tokyo); 1980 Sep; 33(9):1048-53. PubMed ID: 6160136
[TBL] [Abstract][Full Text] [Related]
27. Anthracyclines as tumor cell differentiating agents: effects on the regulation of erythroid gene expression.
Jeannesson P; Lahlil R; Chenais B; Devy L; Gillet R; Aries A; Morceau F; Trentesaux C
Leuk Lymphoma; 1997 Aug; 26(5-6):575-87. PubMed ID: 9389364
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity.
Marsh JC; Brown BJ; Nierenburg MM
Cancer Res; 1983 Jun; 43(6):2962-6. PubMed ID: 6573955
[TBL] [Abstract][Full Text] [Related]
29. New anthracycline antibiotics.
Oki T
Jpn J Antibiot; 1977 Dec; 30 Suppl():70-84. PubMed ID: 612711
[TBL] [Abstract][Full Text] [Related]
30. Comparative murine metabolism and disposition of class II anthracycline antibiotics.
Dodion P; Egorin MJ; Riggs CE; Ferraro TA; Tamburini JM; Bachur NR
Cancer Chemother Pharmacol; 1985; 15(2):153-60. PubMed ID: 3860304
[TBL] [Abstract][Full Text] [Related]
31. Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells.
Morceau F; Aries A; Lahlil R; Devy L; Jardillier JC; Jeannesson P; Trentesaux C
Biochem Pharmacol; 1996 Mar; 51(6):839-45. PubMed ID: 8602880
[TBL] [Abstract][Full Text] [Related]
32. Effects on leukemic clonogenic cells in murine myeloid leukemia of 1-beta-D-arabinofuranosylcytosine and the anthracyclines adriamycin, daunomycin, aclacinomycin A, and 4'-epidoxorubicin.
Nara N; Yamashita Y; Murohashi I; Tanikawa S; Imai Y; Aoki N
Cancer Res; 1987 May; 47(9):2376-9. PubMed ID: 3471325
[TBL] [Abstract][Full Text] [Related]
33. Effect of aclacinomycin-doxorubicin association on differentiation and growth of human erythroleukemic K562 cells.
Nyoung MN; Trentesaux C; Aries A; Carpentier Y; Jardillier JC; Gorisse MC; Jeannesson P
Anticancer Res; 1994; 14(3A):1203-8. PubMed ID: 8074473
[TBL] [Abstract][Full Text] [Related]
34. Ureido derivatives of pyridine: a new class of inducers of murine erythroleukemia cell differentiation.
Pappas IS; Niopas I; Tsiftsoglou AS
Anticancer Drug Des; 1992 Apr; 7(2):153-61. PubMed ID: 1575888
[TBL] [Abstract][Full Text] [Related]
35. Mutagenicity of aclacinomycin A and daunomycin derivatives.
Umezawa K; Sawamura M; Matsushima T; Sugimura T
Cancer Res; 1978 Jun; 38(6):1782-4. PubMed ID: 348304
[TBL] [Abstract][Full Text] [Related]
36. Desorption chemical ionization mass spectrometry of anthracyclines and of trisaccharides related to aclacinomycin A and marcellomycin.
Monneret C; Sellier N
Biomed Environ Mass Spectrom; 1986 Jul; 13(7):319-26. PubMed ID: 2943345
[TBL] [Abstract][Full Text] [Related]
37. Studies on the cytotoxicity, mutagenicity and chromosomal aberration-inducing activity of aclacinomycin A in cultured mammalian cells.
Shuin T; Moriyama M; Nishimura R; Takai S; Umeda M
Gan; 1981 Apr; 72(2):197-204. PubMed ID: 6169583
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects of fagaronine, adriamycin and aclacinomycin on K562 cell sensitivity to natural-killer-mediated lysis. Lack of agreement between alteration of transferrin receptor and CD15 antigen expressions and induction of resistance to natural killer.
Benoist H; Comoe L; Joly P; Carpentier Y; Desplaces A; Dufer J
Cancer Immunol Immunother; 1989; 30(5):289-94. PubMed ID: 2624922
[TBL] [Abstract][Full Text] [Related]
39. Induction of erythropoietin receptors during aclacinomycin-mediated erythroid differentiation of K562 leukemia cells.
Jeannesson P; Trentesaux C; Nyoung MN; Mayeux P; Jacquot R; Jardillier JC
Leukemia; 1991 Jan; 5(1):14-8. PubMed ID: 1847982
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin).
Kerr IG; Archer S; DeAngelis C; Farrell S; Hanna S; McKee J
Invest New Drugs; 1987; 5(2):171-6. PubMed ID: 3477533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
